Dose-Response Study of Iocide Oral Rinse

Gingivitis Clinical Trial

Official title:

Phase II Study: Evaluate Dose-Response of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects of Biological Markers Indicative of Systemic Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01103102
• Other study ID #: HSC20090462H
• Secondary ID: 1R44HL101821-01
• Status: Completed
• Phase: Phase 2
• First received: April 12, 2010
• Last updated: January 27, 2013
• Start date: April 2010
• Est. completion date: April 2012

Study information

• Verified date: January 2013
• Source: Biomedical Development Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to explore the dose-response relationship of Iocide oral rinse in a clinical trial of gingivitis.

Approximately sixty (60) otherwise healthy subjects having gingivitis will be randomized into the 3-month study to provide 40 total evaluable subjects (10 per group). Each study participant will have four visits: a screening visit up to 21 days before the beginning of the trial, a baseline visit at day 1, and visits at weeks 8 and 12. The duration of the dose/range study will be three months to facilitate compliance and ensure timely completion of the Phase II study.

Three dose/regimens will be evaluated against a placebo control oral rinse. Indices for gingivitis, plaque and bleeding will be scored and blood tests will be performed to determine the effect of the antimicrobial oral rinse on relative levels of biological markers of inflammation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: April 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males or non-pregnant females of at least 18 years of age, and in good general health, as determined by Investigator;

• Have at least 16 natural, gradable teeth and good dental health, as determined by Investigator;

• Have > 25% sites with Gingival Index (GI) scores > 2;

• Have average Plaque Index (PI) score > 2;

• Use of effective method of contraception for the duration of the study or permanently sterilized;

• Able and willing to comply with study requirements including following instructions on study treatment and returning for follow-up visits as required by the protocol;

• Have full understanding of all elements of, and signature and dating of the written informed consent prior to the initiation of protocol specified procedures;

• Females with childbearing potential must have a negative pregnancy test before and during the study period. Sexually active females must be using an effective form of birth control or abstinence. These methods include oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrel implants (Norplant®), medroxyprogesterone acetate injections (Depo-provera®) or contraceptive foam with a condom.

Exclusion Criteria:

• History, or current evidence, of any significant acute or chronic subject-reported medical or psychiatric condition that, in the opinion of the Investigator, would render examination difficult or invalid or prevent the subject from active study participation;

• =24% of sites with GI score >2;

• TPOab positive >34;

• Screening serum level of TSH <0.45 or >4.5;

• Treatment with antibiotic within the one (1) month period prior to the screening examination;

• History of heart murmur, history of rheumatic fever, valvular disease or prosthetic implant requiring antibiotic premedication;

• History of thyroid disease;

• Purported sensitivity or allergy to iodine;

• Known sensitivity or allergy to shellfish;

• History of diabetes;

• History of autoimmune disease;

• Gross oral pathology (periodontal disease, rampant caries, tissue damage created by poor oral care or treatment, soft or hard tissue tumors) that, in the opinion of the Investigator, could influence the outcome of the study;

• Periodontal disease screening will be performed by assessing periodontal pocket depths >5mm on six (6) sites per tooth (distofacial, facial, mesiofacial, mesiolingual, lingual and distolingual). A UNC-15 periodontal probe (Hu-Friedy) will be used for all measurements. Any subject with true periodontal pockets > 5 mm will be excluded from participation in this study;

• Current signs or symptoms of mucosal tissue ulcerations or inflammation, or canker sores;

• Presence of orthodontic appliances or any removable appliance that impinges on the oral tissues being assessed;

• History of early onset periodontal disease or acute necrotizing ulcerative gingivitis;

• Subject reported history in past 6 months or current alcohol abuse that, in the opinion of the Investigator, could influence the outcome of the study;

• Subject reported history of last past 6 months or current drug abuse;

• Use of concomitant medication that, in the opinion of the Investigator, might interfere with the outcome of the study (e.g. antibiotics, immuno-suppressants, steroids, or therapeutic doses of non-steroidal anti-inflammatory agents, phenytoin, calcium antagonists, cyclosporine or coumadin);

• Concomitant therapy with another investigational drug or device without prior approval from the Sponsor within four weeks prior to Visit 2 (Study Day 1);

• Concomitant endodontic or periodontal therapy other than prophylaxis in the past six (6) months;

• Females with childbearing potential with a positive pregnancy test, pregnant or nursing mothers, suspected pregnancy, or intention to become pregnant during the study;

• Residence in the same household as a subject already enrolled in the study (inclusion may create blinding and/or compliance issues);

• Unable and unwilling to comply with the informed consent process, to meet study requirements including following instructions on study intervention, and to return for follow-up visits as required by the protocol;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gingivitis

Intervention

Drug:
• Iocide Oral Rinse
Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
• Placebo
Placebo

Locations

Country	Name	City	State
United States	University of Texas Health Science Center at San Antonio	San Antonio	Texas

Sponsors (3)

Lead Sponsor	Collaborator
Biomedical Development Corporation	National Heart, Lung, and Blood Institute (NHLBI), University of Texas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gingival Index	The primary outcome measure will be the mean gingival index (GI) score.	Study Day -21 to -7 through Study Day 84	No